文献速递前列腺癌

前列腺健康指数在中国男性前列腺癌检测中的成本效果

The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-06-30

本研究采用马尔可夫模型评估在中国50-75岁男性中,以PHI(前列腺健康指数)为基础的前列腺癌检测策略相比PSA策略的成本效果。结果显示PHI策略人均总成本更低(USD 22,877 vs 27,439),效果更高(16.05 vs 15.70 QALY),ICER为USD -13,056.56,在100%的蒙特卡洛模拟中更具成本效果。结论支持在中国男性(尤其香港)考虑PHI为基础的筛查策略。

要点

  • PHI策略较PSA策略人均节省USD 4,562并增加0.35 QALY
  • PHI策略在单因素敏感性分析和100%蒙特卡洛模拟中稳健占优
  • 结果支持在中国男性中考虑PHI为基础的前列腺癌检测策略

核心结论

  • 基于PHI的筛查策略可能比基于PSA的策略在中国男性前列腺癌检测中更具成本效果。

研究设计与样本

  • 构建马尔可夫模型模拟中国50-75岁男性,从50岁至75岁共25个筛查周期。
  • PSA策略:对PSA 4-10 ng/mL者行TRUS-PB;PHI策略:对PSA 4-10 ng/mL者检测PHI,仅PHI>35.0者行TRUS-PB。
  • 模型输入优先采用本地数据,计算两种策略的成本、QALY及ICER,并行单因素和概率敏感性分析及成本效果可接受曲线。

主要发现

  • PSA策略人均总成本USD 27,439,效果15.70 QALY;PHI策略人均总成本USD 22,877,效果16.05 QALY。
  • PHI策略预期节省成本USD 4,562并增加0.35 QALY,ICER为USD -13,056.56。
  • 单因素敏感性分析显示结果稳健;蒙特卡洛模拟中PHI策略在100%的迭代中更具成本效果。
  • 无论采用何种WTP阈值,PHI策略均显示对PSA策略的占优。

关键数值与推荐

  • PSA策略:PSA 4-10 ng/mL者行TRUS-PB。
  • PHI策略:PSA 4-10 ng/mL者检测PHI,仅PHI>35.0者行TRUS-PB。
  • PHI策略ICER为USD -13,056.56,在100%蒙特卡洛模拟中更具成本效果。

临床怎么用

  • 在中国男性前列腺癌检测中,可考虑采用PHI策略以减少不必要的穿刺活检并节省成本。
  • 对PSA 4-10 ng/mL者先行PHI检测,仅PHI>35.0者行TRUS-PB,可能更具成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate-specific antigen (PSA) and prostate health index (PHI) have been used as biomarkers for prostate cancer detection. In this study, we aimed to evaluate the cost-effectiveness of PHI for prostate cancer detection in Chinese men. METHOD: We developed a Markov model for Chinese male patient aged 50-75 years old. The PSA strategy was to offer TRUS-PB for all patients with elevated PSA of 4-10 ng/mL. The PHI strategy was to offer PHI for patients with elevated PSA of 4-10 ng/mL. TRUS-PB would only be offered for patients with PHI >35.0. Model inputs were extracted from local data when available. The cost per quality-adjusted life years gained for both strategies were calculated. The incremental cost-effectiveness ratios in relation to the willingness-to-pay (WTP) threshold were compared. One-way sensitivity analysis and probabilistic sensitivity analysis were performed. Cost-effectiveness acceptability curves were also constructed. RESULTS: With a Markov model of 25 screening cycles from age 50 to 75 years, the mean total costs per man were estimated to be USD 27,439 in the PSA strategy and USD 22,877 in the PHI strategy. The estimated effects were estimated to be 15.70 in the PSA strategy and 16.05 in the PHI strategy. The PHI strategy was associated with an expected decrease in cost of USD 4562 and an expected gain of 0.35 QALY, resulting in an ICER of USD -13056.56. The results were shown to be robust upon one-way sensitivity analysis. Upon Monte Carlo simulation, the PHI strategy was more cost-effective for 100% of the iterations. The PHI strategy demonstrated dominance over the PSA strategy regardless of what WTP threshold we use. CONCLUSIONS: A PHI-based screening strategy may be more cost-effective than a PSA-based strategy for prostate cancer detection in Chinese men. These results support consideration of a PHI-based approach for prostate cancer in Hong Kong.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Teoh JY, Leung CH, Wang MH, et al. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men. Prostate Cancer Prostatic Dis. 2020. PMID: 32606435. doi:10.1038/s41391-020-0243-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。